Person: KÜTÜKOĞLU, MEHMET UMUT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KÜTÜKOĞLU
First Name
MEHMET UMUT
Name
16 results
Search Results
Now showing 1 - 10 of 16
Publication Open Access Sacral neuromodulation treatment for urinary voiding dysfunctions: Results of treatment with the largest single-center series in a tertiary referral center in Turkey(2022-03-19) KÜTÜKOĞLU, MEHMET UMUT; Umut Kütükoğlu M. U., Altuntaş T., Şahin B., Onur A. R.Background/aim: Sacral neuromodulation (SNM) is a minimally invasive treatment that modulates spinal reflexes to regulate bladder, urinary sphincter, and pelvic floor and has successfully been used in the treatment of refractory voiding dysfunctions. The aim of this study was to present our experience with SNM in a tertiary referral center with the largest number of patients and review the safety and efficacy of the procedure. Materials and methods: A total of 42 patients with refractory lower urinary tract symptoms were included into the study. After an initial test period, patients who showed more than 50% improvement in their symptoms underwent the second stage of SNM. Twelve patients had overactive bladder (OAB), bladder pain syndrome/interstitial cystitis (BPS/IC) and 17 had urinary retention. The clinical success was examined during follow-up by voiding diary, urodynamics, and global response assessment. Results: Between February 2015 and December 2020, a total of 29 patients underwent stages I&II SNM procedures. The mean ages of patients in OAB/BPS group and retention group were 40 (37–57 years) and 35 (27–44 years), respectively. Mean follow-up time was at least 1 year. Overall, 58.5% success rate was observed in OAB, BPS/IC, and urinary retention groups. Global response assessment score in both groups increased significantly (p = 0.001). No statistically significant difference was found between success or failure rates when sex and age were variable parameters (p > 0.05). Conclusion: SNM appears to be an effective and safe treatment option in restoring voiding dysfunctions in patients with refractory idiopathic and neurogenic voiding dysfunctions. Our initial series revealed favorable results; however, further studies with larger series and longer follow-up are needed.Publication Metadata only Bilateral simultane endoskopik taş cerrahisinin (sbes) etkinlik ve güvenlik profilinin değerlendirilmesi(2022-03-13) ŞENER, TARIK EMRE; KÜTÜKOĞLU, MEHMET UMUT; TANIDIR, YILÖREN; ÖZGÜR G., ŞENER T. E., KÜTÜKOĞLU M. U., TANIDIR Y.Giriş Her iki böbreğinde taş bulunan hastalarda multiple operasyonlardan kaçınmak ve operasyon sürelerini kısaltmak için Bilateral Simultane Endoskopik Taş cerrahisi (SBES) yapılabilmektedir. Bu çalışmamızda bilateral böbrek taşı olan hastalarda SBES'in etkinlik ve güvenlik profilini değerlendirmeyi amaçladık. Method Her iki böbrek taşı için tedavi endikasyonu bulunan ve aynı seansta bir böbreğine supin perkütan nefrolitotomi (PNL), diğer böbreğine fleksible üreterorenoskopi (FURS) yapılan hastalar prospektif olarak çalışmaya dahil edildi. Hastalar ameliyat öncesi ve sonrası kan ve idrar testleri ile ameliyat öncesi kontrastsız BT taramasını içeren standart bir ürolitiazis tanı yaklaşımı ile değerlendirildi. Çalışmamızda elde etmek istediğimiz birincil sonuç taşsızlık durumunu (fragmanlar <3mm) ve komplikasyonları belirleyerek SBES'in güvenlik ve etkinlik profilini değerlendirmektir. İkincil sonuç ise hastanede kalış süresi, floroskopi dozu ve ameliyat sonrası çıkış stratejisini değerlendirmektir. Bulgular Çalışmaya 45 hasta (Erkek/kadın : 31/14) dahil edildi. Hastaların ortanca yaşı 51 idi (min 27 , Mak 90) Hastaların PCNL ile tedavi edilen böbrekteki ortanca taş hacmi 2880,4 mm3 (min 644,4 mak 62724,2) ve FURS ile tedavi edilen böbrekteki ortanca taş hacmi 543,64 mm3 (min 43,3 mak 11291,2) idi. Ortanca operasyon süresi 150 dakika ve ortanca floroskopi dozu 41.08 mGy idi. (Tablo 1.) PCNL uygulanan böbrek tarafından 35 (77,8%) hastada, FURS uygulanan böbrek tarafında 36 (80%) hastada taşsızlık sağlandı. PCNL uygulanan böbrekte saptanan ortanca rezidüel taş fragmanı 7.5 mm (min 2 max 12) ve FURS uygulanan böbrekte saptanan ortanca rezidüel taş fragmanı 7 mm (min 1 max 15) olarak saptandı. PCNL uygulamasında 6 (%13,3) hastada 12-16 Fr, 1 (%2,2) hastada 14-18 Fr , 22 (%48,9) hastada 16 - 20 Fr, 1 (%2,2) hastada 20-24 Fr ve kalan 15 (%33,4) hastada 26-30 Fr amplatz kılıf kullanılmıştır. Taşların kırılması için 28 (%62,2) hastada lazer litotripsi, 14 (%13,3) hastada balistik litotripsi, 2 (%4,2) hastada her iki yöntem ve 1 (%2,2) hastada taşın mekanik olarak ekstraksiyonu uygulandı. FURS uygulamasında 2 (%4,4) hastada üreteral akses kılıfı (ÜAK) kullanılmamış olup 19 (%42,2) hastada 9,5/11,5 Fr; 4 (%8,9) hastada 10/12 Fr; 20 (%44,4) hastada 12/14 Fr ÜAK kullanıldı. Tüm hastalarda taş tedavisi için lazer litotripsi kullanıldı. Sonuç Bilateral Simultane Endoskopik Taş cerrahisi (SBES) , seçilmiş hastalarda güvenli ve uygulanabilir bir yöntem olarak görünmektedir ancak en az 2 deneyimli cerrah ve iyi donanımlı bir hastaneye ihtiyaç vardır.Publication Metadata only İskemi uygulanmadan ve parankim onarimi yapilmadan gerçekleştirilen laparoskopik parsiyel nefrektomi güvenli mi?(2020-11-15) ŞAHİN, BAHADIR; KÜTÜKOĞLU, MEHMET UMUT; ŞAHİN B., KÜTÜKOĞLU M. U., TİNAY İ.Publication Open Access The association of urinary BDNF, ATP, and MMP-2 with bladder compliance in children with myelodysplasia(2023-01-01) ŞEKERCİ, ÇAĞRI AKIN; KÜTÜKOĞLU, MEHMET UMUT; YÜCEL, SELÇUK; TARCAN, TUFAN; ŞEKERCİ Ç. A., KÜTÜKOĞLU M. U., Basok B. I., Fidan M., ÇAM S., YÜCEL S., TARCAN T.Aim: The purpose of our study was to evaluate the relationship of urinary brain-derived neurotrophic factor (BDNF), adenosine triphosphate (ATP), matrix metallopreteinase-2 (MMP-2) with urodynamic findings and upper urinary tract deterioration (UUTD) in children with myelodysplasia. Materials and Methods: Children with myelodysplasia evaluated in outpatient clinic between 2022 and 2023 were included. All patients underwent urinary ultrasonography, voiding cystourethrography, urodynamics, and DMSA scintigraphy. Urine samples were collected before urodynamics. Control urine was collected from 10 healthy children. Urinary biomarker values of patients and controls were compared, and subgroup analysis was performed. Results: The median age of 40 children (26 girls) included in the study was 108 (8–216) months, and the control group (six girls) was 120 (60–154) (p = 0.981). Urinary BDNF, MMP-2, and ATP were found to be significantly higher in children with myelodysplasia compared to the control (p = 0.007, p = 0.027, p = 0.014, respectively). The three biomarker values were similar in children with bladder compliance below or above 10 cmH2O/mL (p = 0.750, p = 0.844, p = 0.575). No difference was found in terms of UUTD in all three biomarkers (p = 0.387, p = 0.892, p = 0.705). A negative correlation was found between urinary ATP and compliance (p < 0.05). Conclusion: In this study, all three biomarkers were found to be higher in children with myelodysplasia than in controls. There was a negative correlation between urinary ATP and compliance. Urinary biomarkers may contribute the follow-up of children with neurogenic lower urinary tract deterioration in future with their noninvasive features. However, the lack of standardization and the inability to reliably predict risky groups are important shortcomings of urinary biomarkers.Publication Open Access Sacral neur al neuromodulation tr omodulation treatment for urinar eatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a ter series in a tertiary referral center in T al center in Turkey(2023-02-01) KÜTÜKOĞLU, MEHMET UMUT; ALTUNTAŞ, TÜRKER; ŞAHİN, BAHADIR; ONUR, AHMET RAHMİ; KÜTÜKOĞLU M. U., ALTUNTAŞ T., ŞAHİN B., ONUR A. R.BACKGROUND: Sacral neuromodulation (SNM) is a minimally invasive treatment that modulates spinal reflexes to regulate bladder, urinary sphincter, and pelvic floor and has successfully been used in the treatment of refractory voiding dysfunctions. The aim of this study was to present our experience with SNM in a tertiary referral center with the largest number of patients and review the safety and efficacy of the procedure. METHODS: A total of 42 patients with refractory lower urinary tract symptoms were included into the study. After an initial test period, patients who showed more than 50% improvement in their symptoms underwent the second stage of SNM. Twelve patients had overactive bladder (OAB), bladder pain syndrome/interstitial cystitis (BPS/IC) and 17 had urinary retention. The clinical success was examined during follow-up by voiding diary, urodynamics, and global response assessment. RESULTS: Between February 2015 and December 2020, a total of 29 patients underwent stages I&II SNM procedures. The mean ages of patients in OAB/BPS group and retention group were 40 (37-57 years) and 35 (27-44 years), respectively. Mean follow-up time was at least 1 year. Overall, 58.5% success rate was observed in OAB, BPS/IC, and urinary retention groups. Global response assessment score in both groups increased significantly (p = 0.001). No statistically significant difference was found between success or failure rates when sex and age were variable parameters (p > 0.05). DISCUSSION: SNM appears to be an effective and safe treatment option in restoring voiding dysfunctions in patients with refractory idiopathic and neurogenic voiding dysfunctions. Our initial series revealed favorable results; however, further studies with larger series and longer follow-up are needed.Publication Metadata only The value of urinary BDNF, ATP And MMP-2 in children with myelodysplasia(2023-09-27) ŞEKERCİ, ÇAĞRI AKIN; KÜTÜKOĞLU, MEHMET UMUT; YÜCEL, SELÇUK; TARCAN, TUFAN; Şekerci Ç. A., Kütükoğlu M. U., İşbilen Başok B., Fidan M., Yücel S., Tarcan T.HYPOTHESIS / AIMS OF STUDYStudies on the effects of various urinary biomarkers in children with neurogenic or non-neurogenic lower urinary tract dysfunction (LUTD) have been published in recent years. Three of them are Brain Derived Neurotrophic Factor (BDNF), Adenosine Triphosphate (ATP), Matrix Metallopreteinase-2 (MMP-2), and various positive effects in diagnosis and follow-up have been reported in different patient groups. In this study, it was aimed to evaluate the relationship of these urinary biomarkers with urodynamic findings and upper urinary tract deterioration (UTTD) in children with myelodysplasia.STUDY DESIGN, MATERIALS AND METHODSChildren with myelodysplasia evaluated in the pediatric urology outpatient clinic between 2022 and 2023 were included in the study. All patients underwent urinary ultrasonography, voiding cystourethrography, urodynamic studies, and DMSA renal scintigraphy. Children with missing data were excluded from the study. Urine samples were collected into sterile urine collection tubes before urodynamics. After each urine sample was centrifuged at 3000 g for 10 minutes, the supernatant was separated and stored at -800C until further analysis. In addition, control urine was collected from 10 healthy children. Urinary BDNF, ATP, and MMP-2 were studied by ELISA method. Urinary biomarker values of patients and controls were compared and subgroup analysis was performed in the myelodysplasia group in terms of urodynamic findings and UUTD. The presence of renal scar, vesicoureteral reflux, or hydronephrosis was considered as UUTD. Constipation status was evaluated with the Bristol stool chart.RESULTSThe median age of 40 children (26 girls (65%), 14 boys (35%)) included in the study was 108 (8-216) months, and the healthy control group (6 girls, 4 boys) was 120 (60-154) months (p=0.981). The primary etiology of 35 children was myelomeningocele (87.5%), 2 dermal sinus (5%), 2 tethered cord (5%), and one sacrococcygeal immature teratoma (2.5%). Urinary BDNF, MMP-2, and ATP were found to be significantly higher in children with myelodysplasia compared to the control group (p=0.007, p=0.027, p=0.014, respectively) (Table 1). In the subgroup analysis, the three biomarker values were similar in children with bladder compliance below or above 10 cmH2O/ml (p=0.750, p=0.844, p=0.575). In addition, no difference was found in terms of UUTD in all three biomarkers (p=0.387, p=0.892, p=0.705). However, a negative correlation was found between urinary ATP and bladder compliance in the correlation analysis (p<0.05) (Table 2). Interestingly, a positive correlation was detected among the three biomarkers (p<0.01) (Table 2). There was no significant difference in urinary biomarkers between children with and without constipation.INTERPRETATION OF RESULTSInvasive urodynamic studies are the gold standard method in the evaluation of children with neurogenic LUTD after first-step tests. In recent years, it is tried to define tests that help and support urodynamic studies in the diagnosis and follow-up of these children. Among these, urine biomarkers come to the forefront with their easy-to-measure features. Three biomarkers evaluated in this study were found to be higher in children with myelodysplasia compared to the healthy control group. However, in subgroup analyses, they were not found to be significantly different in children with UUTD. One of these, urinary BDNF, is the most frequently studied biomarker in children with LUTD after NGF. Urinary BDNF has only been studied in one study in children with myelodysplasia, and decreased after the intravesical injection of botulinum toxin (1). Urinary MMP-2 has been previously studied in adults with spina bifida, and ATP in women with overactive bladders, and significant findings on both biomarkers have been reported (2,3). To our knowledge, these two biomarkers have been studied for the first time in children. In particular, we think that the negative relationship between urinary ATP and bladder compliance may be significant in clinical follow-up. The small number of patients seems to be the most important limitation of the study.CONCLUDING MESSAGEUrinary biomarkers seem promising for the future with their non-invasive features in the follow-up of children with neurogenic LUTD. However, the lack of standardization, the inconsistency between the results of the studies, and the inability to reliably predict risky groups are important shortcomings of urinary biomarkers. We consider that urinary biomarkers should only be assessed as a part of well-designed studies and should not be used in the clinical decision-making process of neurogenic LUTD in children.FIGURE 1Table 1. Comparison of urinary BDNF, ATP and MMP-2 values between patients and controlsFIGURE 2Table 2. Correlations for bladder compliance, ATP, BDNF and MMP-2 in patientsREFERENCESSekerci CA, Tanidir Y, Toprak T, Basok BI, Isman F, Simsek F, et al. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia. J Urol. 2019;201(1):174-80.Peyronnet B, Richard C, Bendavid C, Naudet F, Hascoet J, Brochard C, Senal N, Jezequel M, Alimi Q, Khene ZE, Corlu A, Clément B, Siproudhis L, Bouguen G, Kerdraon J, Manunta A, Gamé X. Urinary TIMP-2 and MMP-2 are significantly associated with poor bladder compliance in adult patients with spina bifida. Neurourol Urodyn. 2019 Nov;38(8):2151-2158. doi: 10.1002/nau.24163. Epub 2019 Sep 4. PMID: 31486131.Silva-Ramos M, Silva I, Oliveira O, Ferreira S, Reis MJ, Oliveira JC, Correia-de-Sá P. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome. PLoS One. 2013 May 31;8(5):e64696. doi: 10.1371/journal.pone.0064696. PMID: 23741373; PMCID: PMC3669404.Publication Metadata only Bi̇lateral si̇multane endoskopi̇k taş cerrahi̇si̇ni̇n (sbes) etki̇nli̇k ve güvenli̇k profi̇li̇ni̇n değerlendi̇ri̇lmesi̇(2022-03-10) ÖZGÜR, GÜNAL; ŞENER, TARIK EMRE; KÜTÜKOĞLU, MEHMET UMUT; TANIDIR, YILÖREN; Özgür G., Şener T. E., Kütükoğlu M. U., Tanıdır Y.Giriş Her iki böbreğinde taş bulunan hastalarda multiple operasyonlardan kaçınmak ve operasyon sürelerini kısaltmak için Bilateral Simultane Endoskopik Taş cerrahisi (SBES) yapılabilmektedir. Bu çalışmamızda bilateral böbrek taşı olan hastalarda SBES'in etkinlik ve güvenlik profilini değerlendirmeyi amaçladık. Method Her iki böbrek taşı için tedavi endikasyonu bulunan ve aynı seansta bir böbreğine supin perkütan nefrolitotomi (PNL), diğer böbreğine fleksible üreterorenoskopi (FURS) yapılan hastalar prospektif olarak çalışmaya dahil edildi. Hastalar ameliyat öncesi ve sonrası kan ve idrar testleri ile ameliyat öncesi kontrastsız BT taramasını içeren standart bir ürolitiazis tanı yaklaşımı ile değerlendirildi. Çalışmamızda elde etmek istediğimiz birincil sonuç taşsızlık durumunu (fragmanlar <3mm) ve komplikasyonları belirleyerek SBES'in güvenlik ve etkinlik profilini değerlendirmektir. İkincil sonuç ise hastanede kalış süresi, floroskopi dozu ve ameliyat sonrası çıkış stratejisini değerlendirmektir. Bulgular Çalışmaya 45 hasta (Erkek/kadın : 31/14) dahil edildi. Hastaların ortanca yaşı 51 idi (min 27 , Mak 90) Hastaların PCNL ile tedavi edilen böbrekteki ortanca taş hacmi 2880,4 mm3 (min 644,4 mak 62724,2) ve FURS ile tedavi edilen böbrekteki ortanca taş hacmi 543,64 mm3 (min 43,3 mak 11291,2) idi. Ortanca operasyon süresi 150 dakika ve ortanca floroskopi dozu 41.08 mGy idi. (Tablo 1.) PCNL uygulanan böbrek tarafından 35 (77,8%) hastada, FURS uygulanan böbrek tarafında 36 (80%) hastada taşsızlık sağlandı. PCNL uygulanan böbrekte saptanan ortanca rezidüel taş fragmanı 7.5 mm (min 2 max 12) ve FURS uygulanan böbrekte saptanan ortanca rezidüel taş fragmanı 7 mm (min 1 max 15) olarak saptandı. PCNL uygulamasında 6 (%13,3) hastada 12-16 Fr, 1 (%2,2) hastada 14-18 Fr , 22 (%48,9) hastada 16 - 20 Fr, 1 (%2,2) hastada 20-24 Fr ve kalan 15 (%33,4) hastada 26-30 Fr amplatz kılıf kullanılmıştır. Taşların kırılması için 28 (%62,2) hastada lazer litotripsi, 14 (%13,3) hastada balistik litotripsi, 2 (%4,2) hastada her iki yöntem ve 1 (%2,2) hastada taşın mekanik olarak ekstraksiyonu uygulandı. FURS uygulamasında 2 (%4,4) hastada üreteral akses kılıfı (ÜAK) kullanılmamış olup 19 (%42,2) hastada 9,5/11,5 Fr; 4 (%8,9) hastada 10/12 Fr; 20 (%44,4) hastada 12/14 Fr ÜAK kullanıldı. Tüm hastalarda taş tedavisi için lazer litotripsi kullanıldı. Sonuç Bilateral Simultane Endoskopik Taş cerrahisi (SBES) , seçilmiş hastalarda güvenli ve uygulanabilir bir yöntem olarak görünmektedir ancak en az 2 deneyimli cerrah ve iyi donanımlı bir hastaneye ihtiyaç vardır. Anahtar Kelimeler : BİLATERAL SİMULTANE ENDOSKOPİK TAŞ CERRAHİSİ (SBES), SUPİN PERKÜTAN NEFROLİTOTOMİ (sPCNL) , FLEKSİBLE ÜRETERORENOSKOPİ (FURS)Publication Open Access A survey study on evaluation and management of nocturnal enuresis in pediatricians and family physicians(2023-09-01) ŞEKERCİ, ÇAĞRI AKIN; KÜTÜKOĞLU, MEHMET UMUT; DÖRÜCÜ, DOĞANCAN; TANIDIR, YILÖREN; ÇAM, HAYDAR KAMİL; TARCAN, TUFAN; YÜCEL, SELÇUK; Şekerci Ç. A., Kütükoğlu M. U., Dörücü D., Ergün R., Tanıdır Y., Çam H. K., Tarcan T., Yücel S.Objective:Nocturnal enuresis (NE) is one of the most common disorders in pediatric urology, and patients often turn to family physicians (FP) and pediatricians (P) initially. The aim of this study was to understand the awareness, self-confidence and suggestions of physicians regarding the management of NE.Materials and Methods:In this study, 360 FP and family medicine residents (FMR), as well as 280 P and pediatrics residents (PR), were contacted through a cellular phone texting system. A simple multiple-choice questionnaire (Surveymonkey®) consisting of 10 questions was used to gather data. The survey included questions about their experience, training, evaluation, and management of NE.Results:A total of 119 FPs and Ps (18.5%) filled the questionnaire. Thirty (25.21%) of the participants were P, 27 (22.69%) PR, 3 (2.52%) FP and 59 (49.58%) FMR. The rate of physicians who encounter at least 5 children with NE per month is 31.33%. The mean self-confidence in the management of NE was 4.5 out of 10. The self-confidence of pediatricians was significantly higher than that of PR and FMR (p<0.001, p<0.001). Most (n=78, 65.55%) of the participants stated that they received training on EN during medical faculty and 62 (52.10%) during residency. Psychological problems (89.92%), sleep disorders (78.15%), and excessive fluid intake (75.63%) were the most frequently considered factors in etiology. While most responders (75.63%) considered dietary regulation and behavioral interventions as the first-line treatment, 25.21% consult a pediatric urologist and only 1.6% recommend medical treatment.Conclusion:Although FP and P admit they had training on NE, they mostly felt incompetent to manage NE and exclusively avoided pharmacological treatment.Keywords:Children, enuresis nocturna, pediatric urology, physicians, surveyPublication Metadata only Evaluation of depression and anxiety conditions in patients with lower urinary tract symptoms(2022-09-07) KÜTÜKOĞLU, MEHMET UMUT; ŞEKERCİ, ÇAĞRI AKIN; ÇAM, HAYDAR KAMİL; TARCAN, TUFAN; Güçtaş A. Ö. , Kütükoğlu M. U. , Şekerci Ç. A. , Tarcan T., Çam H. K.Publication Unknown Prognosis of extended-spectrum-beta-lactamase-producing agents in emphysematous pyelonephritis-results from a large, multicenter series(2022-12-01) TANIDIR, YILÖREN; KÜTÜKOĞLU, MEHMET UMUT; Ivan Robles-Torres J., Castellani D., Trujillo-Santamaria H., Teoh J. Y., TANIDIR Y., Gadu Campos-Salcedo J., Ivan Bravo-Castro E., Langer Wroclawski M., Kumar S., Eduardo Sanchez-Nunez J., et al.Background: Emphysematous pyelonephritis (EPN) is a necrotizing infection of the kidney and surrounding tissues with significant mortality. We aimed to assess the clinical factors and their influence on prognosis in patients being managed for EPN with and without ESBL-producing bacteria and to identify if those with EPN due to ESBL infections fared any different. Methods: A retrospective analysis was performed on patients with EPN diagnosis from 22 centers across 11 countries (between 2013 and 2020). Demographics, clinical presentation, biochemical parameters, radiological features, microbiological characteristics, and therapeutic management were assessed. Univariable and multivariable analyses were performed to determine the independent variables associated with ESBL pathogens. A comparison of ESBL and non-ESBL mortality was performed evaluating treatment modality. Results: A total of 570 patients were included. Median (IQR) age was 57 (47-65) years. Among urine cultures, the most common isolated pathogen was Escherichia coli (62.2%). ESBL-producing agents were present in 291/556 urine cultures (52.3%). In multivariable analysis, thrombocytopenia (OR 1.616 95% CI 1.081-2.413, p = 0.019), and Huang-Tseng type 4 (OR 1.948 95% CI 1.005-3.778, p= 0.048) were independent predictors of ESBL pathogens. Patients with Huang-Tseng Scale type 1 had 55% less chance of having ESBL-producing pathogens (OR 1.616 95% CI 1.081-2.413, p = 0.019). Early nephrectomy (OR 2.3, p = 0.029) and delayed nephrectomy (OR 2.4, p = 0.015) were associated with increased mortality in patients with ESBL infections. Conservative/minimally invasive management reported an inverse association with mortality (OR 0.314, p = 0.001). Conclusions: ESBL bacteria in EPN were not significantly associated with mortality in EPN. However, ESBL infections were associated with poor prognosis when patients underwent nephrectomy compared conservative/minimally invasive management.